{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:04Z","timestamp":1790665324830,"version":"4.1.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Non-alcoholic fatty liver disease (NAFLD) is one of the fastest-growing diseases, and its global prevalence is estimated to increase &gt;50% by 2030. NAFLD is comorbid with metabolic syndrome, obesity, type 2 diabetes, and insulin resistance. Despite extensive research efforts, there are no pharmacologic or biological therapeutics for the treatment of NAFLD. Bile acids and sphingolipids are well-characterized signaling molecules. Over the last few decades, researchers have uncovered potential mechanisms by which bile acids and sphingolipids regulate hepatic lipid metabolism. Dysregulation of bile acid and sphingolipid metabolism has been linked to steatosis, inflammation, and fibrosis in patients with NAFLD. This clinical observation has been recapitulated in animal models, which are well-accepted by experts in the hepatology field. Recent transcriptomic and lipidomic studies also show that sphingolipids are important players in the pathogenesis of NAFLD. Moreover, the identification of bile acids as activators of sphingolipid-mediated signaling pathways established a novel theory for bile acid and sphingolipid biology. In this review, we summarize the recent advances in the understanding of bile acid and sphingolipid-mediated signaling pathways as potential contributors to NAFLD. A better understanding of the pathologic effects mediated by bile acids and sphingolipids will facilitate the development of new diagnostic and therapeutic strategies for NAFLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002156","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T09:00:14Z","timestamp":1657011614000},"page":"1163-1171","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":36,"title":["Bile acids and sphingolipids in non-alcoholic fatty liver disease"],"prefix":"10.1097","volume":"135","author":[{"given":"Kaitlyn G.","family":"Jackson","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grayson W.","family":"Way","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA"},{"name":"Central Virginia Veterans Healthcare System, Richmond, VA 23249, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cld.1061","article-title":"Global epidemiology of chronic liver disease","volume":"17","author":"Cheemerla","year":"2021","journal-title":"Clin Liver Dis"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","article-title":"MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy","volume":"134","author":"Xian","year":"2020","journal-title":"Chin Med J"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10409238.2017.1337706","article-title":"Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology","volume":"52","author":"Rohrbach","year":"2017","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1194\/jlr.M093799","article-title":"FTY720\/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice","volume":"60","author":"Rohrbach","year":"2019","journal-title":"J Lipid Res"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/jcm10020346","article-title":"Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a cross-sectional retrospective study","volume":"10","author":"Tarantino","year":"2021","journal-title":"J Clin Med"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in NAFLD - revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2020.12.016","article-title":"Clinical utility of the MAFLD definition","volume":"74","author":"Zheng","year":"2021","journal-title":"J Hepatol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/CM9.0000000000000981","article-title":"From NAFLD to MAFLD: a \u201credefining\u201d moment for fatty liver disease","volume":"133","author":"Zheng","year":"2020","journal-title":"Chin Med J"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"716783","DOI":"10.3389\/fnut.2021.716783","article-title":"Dietary interventions in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"8","author":"Houttu","year":"2021","journal-title":"Front Nutr"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tem.2017.03.005","article-title":"Sphingolipids and lipoproteins in health and metabolic disorders","volume":"28","author":"Iqbal","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/bs.acr.2018.05.002","article-title":"Sphingolipids at the crossroads of NAFLD and senescence","volume":"140","author":"Nikolova-Karakashian","year":"2018","journal-title":"Adv Cancer Res"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/ijms21010040","article-title":"Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover","volume":"21","author":"Simon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cmet.2021.06.006","article-title":"Sphingolipids in metabolic disease: the good, the bad, and the unknown","volume":"33","author":"Green","year":"2021","journal-title":"Cell Metab"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/j.2040-4603.2022.tb00205.x","article-title":"Bile acids, gut microbiome and the road to fatty liver disease","volume":"12","author":"Hylemon","year":"2021","journal-title":"Compr Physiol"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/cells10112806","article-title":"Bile acid receptors and the gut-liver axis in nonalcoholic fatty liver disease","volume":"10","author":"Xue","year":"2021","journal-title":"Cells"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/hep.31599","article-title":"NAFLD: reporting histologic findings in clinical practice","volume":"73","author":"Brunt","year":"2021","journal-title":"Hepatology"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5009\/gnl20127","article-title":"Recent epidemiology of nonalcoholic fatty liver disease","volume":"15","author":"Murag","year":"2021","journal-title":"Gut Liver"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/cells8111358","article-title":"Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression","volume":"8","author":"Gottlieb","year":"2019","journal-title":"Cells"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease","volume":"159","author":"Hofmann","year":"1999","journal-title":"Arch Intern Med"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fendo.2017.00047","article-title":"Cholecystokinin-from local gut hormone to ubiquitous messenger","volume":"8","author":"Rehfeld","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/164_2019_230","article-title":"Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors","volume":"256","author":"Keitel","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bbalip.2013.08.006","article-title":"Sphingolipids and lifespan regulation","volume":"1841","author":"Huang","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.3390\/ijms22158171","article-title":"Stereoselective synthesis of novel sphingoid bases utilized for exploring the secrets of sphinx","volume":"22","author":"Saied","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"27855","DOI":"10.1074\/jbc.R111.254359","article-title":"Many ceramides","volume":"286","author":"Hannun","year":"2011","journal-title":"J Biol Chem"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/jcm10040792","article-title":"Roles of ceramides in non-alcoholic fatty liver disease","volume":"10","author":"Hajduch","year":"2021","journal-title":"J Clin Med"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-030-21735-8_15","article-title":"Roles of ceramides and other sphingolipids in immune cell function and inflammation","volume":"1161","author":"Albeituni","year":"2019","journal-title":"Adv Exp Med boil"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev.biochem.78.072407.103733","article-title":"Sphingosine 1-phosphate receptor signaling","volume":"78","author":"Rosen","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fphar.2017.00579","article-title":"Sphingosine 1-phosphate signaling as a target in hepatic fibrosis therapy","volume":"8","author":"Gonz\u00e1lez-Fern\u00e1ndez","year":"2017","journal-title":"Front Pharmacol"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0300-595X(76)80028-X","article-title":"Starvation in man","volume":"5","author":"Cahill","year":"1976","journal-title":"Clin Endocrinol Metab"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","article-title":"Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease","volume":"158","author":"Azzu","year":"2020","journal-title":"Gastroenterology"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1194\/jlr.RA120000875","article-title":"Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease","volume":"61","author":"Anderson","year":"2020","journal-title":"J Lipid Res"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J Clin Invest"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","volume":"116","author":"Nimer","year":"2021","journal-title":"Metabolism"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cells10020210","article-title":"Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/hep4.1665","article-title":"Serum bile acid, vitamin E, and serotonin metabolites are associated with future liver-related events in nonalcoholic fatty liver disease","volume":"5","author":"Wegermann","year":"2021","journal-title":"Hepatol Commun"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/liv.15030","article-title":"Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus","volume":"41","author":"Jung","year":"2021","journal-title":"Liver Int"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1194\/jlr.M004929","article-title":"Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway","volume":"51","author":"Cao","year":"2010","journal-title":"J Lipid Res"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.20942","article-title":"Conjugated bile acids promote ERK1\/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes","volume":"42","author":"Dent","year":"2005","journal-title":"Hepatology"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.27592","article-title":"Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression","volume":"61","author":"Nagahashi","year":"2015","journal-title":"Hepatology"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.1176709","article-title":"Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate","volume":"325","author":"Hait","year":"2009","journal-title":"Science"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/17474124.2021.1854089","article-title":"Role of histone deacetylase on nonalcoholic fatty liver disease","volume":"15","author":"Fu","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1074\/jbc.RA119.011913","article-title":"Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice","volume":"295","author":"Takahashi","year":"2020","journal-title":"J Biol Chem"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12944-015-0053-y","article-title":"Sphingolipids in cardiovascular diseases and metabolic disorders","volume":"14","author":"Borodzicz","year":"2015","journal-title":"Lipids Health Dis"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biochi.2018.07.021","article-title":"Sphingolipid metabolism in non-alcoholic fatty liver diseases","volume":"159","author":"R\u00e9gnier","year":"2019","journal-title":"Biochimie"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1248\/bpb.35.369","article-title":"Fenretinide ameliorates insulin resistance and fatty liver in obese mice","volume":"35","author":"Koh","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bph.14869","article-title":"Fenretinide treatment accelerates atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects","volume":"177","author":"Busnelli","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R65-20250603","article-title":"The risk of cirrhosis and its complications based on PNPLA3 rs738409 G allele frequency","author":"Shao","year":"2021","journal-title":"Dig Dis"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.31609","article-title":"Identification of a metabolic, transcriptomic, and molecular signature of patatin-like phospholipase domain containing 3-mediated acceleration of steatohepatitis","volume":"73","author":"Banini","year":"2021","journal-title":"Hepatology"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/intimm\/dxz037","article-title":"Sphingosine 1-phosphate and inflammation","volume":"31","author":"Obinata","year":"2019","journal-title":"Int Immunol"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.3748\/wjg.v12.i46.7413","article-title":"Role of kupffer cells in the pathogenesis of liver disease","volume":"12","author":"Kolios","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1194\/jlr.M063511","article-title":"SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes","volume":"56","author":"Geng","year":"2015","journal-title":"J Lipid Res"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"G794","DOI":"10.1152\/ajpgi.00390.2014","article-title":"Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease","volume":"308","author":"Min","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"E756","DOI":"10.1152\/ajpendo.00549.2013","article-title":"Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance","volume":"306","author":"Wang","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fphar.2020.01084","article-title":"Mechanism of hydrophobic bile acid-induced hepatocyte injury and drug discovery","volume":"11","author":"Wei","year":"2020","journal-title":"Front Pharmacol"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1021\/acs.jmedchem.1c01017","article-title":"Recent advances in the medicinal chemistry of farnesoid X receptor","volume":"64","author":"Fang","year":"2021","journal-title":"J Med Chem"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.4254\/wjh.v13.i11.1494","article-title":"Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: from clinical proteomics to microbiome","volume":"13","author":"Castillo-Castro","year":"2021","journal-title":"World J Hepatol"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"154925","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:05:21Z","timestamp":1748977521000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":75,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002156","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]}}}